Literature DB >> 12583375

Clearance of vancomycin during high-volume haemofiltration: impact of pre-dilution.

Shigehiko Uchino1, Louise Cole, Hiroshi Morimatsu, Donna Goldsmith, Rinaldo Bellomo.   

Abstract

OBJECTIVE: To measure the sieving coefficient (SC) and clearance of vancomycin during high-volume haemofiltration (HVHF) and to evaluate the impact of different pre-dilution regimens on these variables. DESIGN AND
SETTING: Prospective interventional study in the intensive care unit in a tertiary university hospital. PATIENTS: Seven patients with septic shock and multi-organ dysfunction.
INTERVENTIONS: HVHF (6 l/h fluid exchange) was performed in septic shock patients using variable proportions of their replacement fluid in pre- and post-dilution mode. MEASUREMENTS AND
RESULTS: Pre-filter, post-filter and ultrafiltrate vancomycin concentrations were measured simultaneously, and SC and clearance calculated. The measurements were repeated following each change in the proportion of pre-dilution fluid. SC steadily decreased as the proportion of pre-dilution decreased, changing from 0.76 in pure pre-dilution to 0.57 in pure post-dilution (p=0.0004). Clearance, however, increased with decreasing pre-dilution fluid rate, from 53.9 ml/min at pure pre-dilution to 67.2 ml/min at 2 l/h pre-dilution with 4 l/h post-dilution.
CONCLUSIONS: HVHF achieves high vancomycin clearances, which despite some deterioration in SC increase with the proportion of replacement fluid given post-filter. Clinicians applying HVHF need to be aware of such clearances to avoid inadequate vancomycin dosing and to adjust therapy according to variations in HVHF technique.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12583375     DOI: 10.1007/s00134-002-1495-z

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  10 in total

Review 1.  Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy.

Authors:  Federico Pea; Pierluigi Viale; Federica Pavan; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 2.  Renal replacement therapies: physiological review.

Authors:  Claudio Ronco; Zaccaria Ricci
Journal:  Intensive Care Med       Date:  2008-09-13       Impact factor: 17.440

3.  Discrepancies between observed and predicted continuous venovenous hemofiltration removal of antimicrobial agents in critically ill patients and the effects on dosing.

Authors:  Catherine S C Bouman; Hendrikus J M van Kan; Richard P Koopmans; Johanna C Korevaar; Marcus J Schultz; Margreeth B Vroom
Journal:  Intensive Care Med       Date:  2006-10-17       Impact factor: 17.440

Review 4.  Antibiotic dosing in critically ill patients with acute kidney injury.

Authors:  Rachel F Eyler; Bruce A Mueller
Journal:  Nat Rev Nephrol       Date:  2011-02-22       Impact factor: 28.314

5.  Longitudinal hemodiafilter performance in modeled continuous renal replacement therapy.

Authors:  Deborah A Pasko; Mariann D Churchwell; Noha N Salama; Bruce A Mueller
Journal:  Blood Purif       Date:  2011-03-02       Impact factor: 2.614

6.  Continuous renal replacement therapy: a worldwide practice survey. The beginning and ending supportive therapy for the kidney (B.E.S.T. kidney) investigators.

Authors:  Shigehiko Uchino; Rinaldo Bellomo; Hiroshi Morimatsu; Stanislao Morgera; Miet Schetz; Ian Tan; Catherine Bouman; Ettiene Macedo; Noel Gibney; Ashita Tolwani; Heleen Oudemans-van Straaten; Claudio Ronco; John A Kellum
Journal:  Intensive Care Med       Date:  2007-06-27       Impact factor: 17.440

7.  Effect of continuous venovenous hemofiltration dose on achievement of adequate vancomycin trough concentrations.

Authors:  Erin N Frazee; Philip J Kuper; Garrett E Schramm; Scott L Larson; Kianoush B Kashani; Douglas R Osmon; Nelson Leung
Journal:  Antimicrob Agents Chemother       Date:  2012-09-17       Impact factor: 5.191

8.  Recommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy.

Authors:  Lucie Seyler; Frédéric Cotton; Fabio Silvio Taccone; Daniel De Backer; Pascale Macours; Jean-Louis Vincent; Frédérique Jacobs
Journal:  Crit Care       Date:  2011-06-06       Impact factor: 9.097

9.  Pharmacokinetics, Pharmacodynamics, and Dose Optimization of Cefiderocol during Continuous Renal Replacement Therapy.

Authors:  Eric Wenzler; David Butler; Xing Tan; Takayuki Katsube; Toshihiro Wajima
Journal:  Clin Pharmacokinet       Date:  2021-11-18       Impact factor: 5.577

10.  Pharmacokinetics and dialytic clearance of apixaban during in vitro continuous renal replacement therapy.

Authors:  Lauren Andrews; Scott Benken; Xing Tan; Eric Wenzler
Journal:  BMC Nephrol       Date:  2021-01-30       Impact factor: 2.388

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.